ClinicalTrials.gg
WithdrawnNCT07336381Replexa+Updated Oct 29, 2026

Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy

An interventional study of Replexa shortwave diathermy in Peripheral Arterial Disease and Peripheral Neuropathy, sponsored by Indiana University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Funding issues
Updated Oct 29, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
360th of 373
0 · median 64
Started
2026
with 14 others
No phase
217 of 479
40 open now
Registered
470th of 479
by date
Lead sponsor
7 of 479
Indiana University

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 360th largest by enrollment of the 373 interventional ones that give a count, is one of 15 that started in 2026, is one of 217 with no phase, and was the 470th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.

Read the detailed description

This is a single-site, non-randomized, open label, exploratory clinical trial to evaluate the effects of the Replexa+ shortwave diathermy treatment in patients diagnosed with peripheral artery disease (PAD) and peripheral neuropathy. This pilot study will examine changes in lower extremity perfusion in a total of ten (10) Veteran patients at the Roudebush VA Medical Center in Indianapolis, Indiana, USA.

The proposed research will study the effects of the Replexa+ device, a Class II, non-invasive device that is cleared to market by the FDA (510k# K162240) and available to prescribing physicians at Veterans Affairs (VA) medical facilities. The Replexa+ device generates a form of electromagnetic energy (shortwave diathermy) to provide therapeutic heat to affected areas, deeper than infrared lights and heating pads. This type of therapeutic heat treatment has been widely used in clinical settings. The Replexa+ system consists of a generating unit (device) connected by a cable to a treatment applicator that is placed against the treated areas over normal clothing. The device operates at 27.12 megahertz (MHz), providing deep heating therapeutic effects to the body tissues.

Patients enrolled in this study will follow the manufacturer's instructions for use of the Replexa+ device and treatment. Treatment will comprise of two 30-minute sessions per day, approximately 8-12 hours apart, for 3 months, at prescribing physician-specified locations of the body.

At the post-treatment visit, the study doctor will assess the success or failure of treatment by comparing baseline measurement testing to post-treatment testing. Treatment failure will be defined as any measurable decrease in limb perfusion as evidenced by lower extremity arterial doppler testing.

03

Conditions studied

  • Peripheral Arterial Disease
  • Peripheral Neuropathy

Keywords

  • peripheral artery disease
  • peripheral neuropathy
  • lower extremity artery disease
  • lower extremity neuropathy
  • PAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of peripheral artery disease (PAD).
  2. Participants must exhibit PAD severity, defined by the following manifestation and corresponding Rutherford classifications:

    Claudication of the index limb (Rutherford Category 2 or 3- documented as pain with walking) in conjunction with one or more of the following:

    • ankle brachial index (ABI) greater than or equal to 0.6 mmHg, as measured no more than 6 months prior to screening
    • resting toe brachial index (TBI) greater than or equal to 0.4, as measured no more than 6 months prior to screening

    Note: In cases where ankle and toe systolic pressures are unavailable due to calcification and/or toe amputation, collection of angiographic data is acceptable to determine locations of blockages or reduced perfusion.

  3. Diagnosis of peripheral neuropathy, as evidenced by review of medical records.
  4. Competent to give consent.
  5. Age 18 years or older.

Exclusion criteria

Exclusion Criteria:

  1. Impaired skin integrity in the location(s) to be treated.
  2. Current wounds or ulcerations.
  3. Diagnosis of active bleeding tendencies, hemorrhage, or thrombosis.
  4. 2+ pitting edema in either lower extremity.
  5. Active infection defined as elevated white blood cell count >11,500/µL or fever >101.5 degrees Fahrenheit or currently taking antibiotic medication(s) for an active infection.
  6. Existence of metal hardware in the area(s) to be treated: Any patient with implanted electronic or metal device such as a pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, IUD, surgical staples or implanted metallic leads.
  7. Pregnant individuals.
  8. Presence of renal disease (creatinine > 2.5 mg/dl and estimated (eGFR) \<30 mL/min) or patients on chronic hemodialysis.
  9. History of skeletal tuberculosis.
  10. Patients, in the investigator's opinion, whose index limb condition is rapidly deteriorating and may require major amputation within 30 days of screening.
  11. Conditions that impair cognitive function.
  12. Severe concomitant disease(s), or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intervention

    In-home shortwave diathermy treatment.

    Device: Replexa shortwave diathermy

Interventions

  • DeviceReplexa shortwave diathermy

    Treatment with home use of the Replexa+ shortwave diathermy device twice daily for 3 months.

06

What researchers measure

Primary outcomes

  1. Compare baseline and post-treatment lower extremity arterial dopplers to determine change in lower extremity arterial perfusion.

    Patients will be treated twice daily for three months with the Replexa+ device. Lower extremity arterial dopplers (LEADs) will be assessed at baseline and post-treatment to determine improvement in lower extremity perfusion.

    Time frame: 3 months

Secondary outcomes

  1. Identify the presence and role of inflammatory biomarkers in PAD.

    Patients will undergo peripheral blood collection at baseline and post-treatment time points to compare levels of high sensitivity C-reactive protein (hsCRP).

    Time frame: 3 months

07

Study locations

1 site
  • Richard L. Roudebush Veterans Affairs Medical Center
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Jul 2026 → Sep 2026, primary completion Dec 2027 → Sep 2026 and completion Dec 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 13, 2026
StartActual
Sep 24, 2026was Jul 2026
Primary completionActual
Sep 24, 2026was Dec 2027
CompletionActual
Sep 24, 2026was Dec 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Funding issues
changed Oct 29, 2026
Start date
Jul 1, 2026→Sep 24, 2026 (actual)
Oct 29, 2026
Primary completion
Dec 31, 2027→Sep 24, 2026 (actual)
Oct 29, 2026
Study completion
Dec 31, 2027→Sep 24, 2026 (actual)
Oct 29, 2026
Enrollment
10 (estimated)→0 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Withdrawn
    Why stopped Funding issues
    Start date Jul 1, 2026→Sep 24, 2026 (now actual)
    Primary completion Dec 31, 2027→Sep 24, 2026 (now actual)
    Study completion Dec 31, 2027→Sep 24, 2026 (now actual)
    Enrollment 10 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07336381
Lead sponsor
Indiana University
Collaborators
ProMedTek, Inc.
Responsible party
Michael Murphy (MD, Indiana University) — Principal investigator
First posted
Jan 13, 2026
Start date
Sep 24, 2026
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026
Last update
Oct 29, 2026

Study contacts

Michael P. Murphy, MD
principal investigator · VA Medical Center, Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion